Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925263 | 0.85 | KCNH2 (0.38) | KCNH2WNT3AACVR1CYP11B1 | |
| SCHEMBL2923193 | 0.84 | CSF1R (0.36) | WNT3AACVR1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2924981 | 0.84 | KCNH2 (0.37) | KCNH2WNT3AACVR1CYP11B1 | |
| SCHEMBL2945776 | 0.82 | CCR1 (0.41) | ACVR1EGFR | |
| SCHEMBL13607692 | 0.73 | LOXL2 (0.44) | KCNH2ACVR1EGFR | |
| SCHEMBL2922147 | 0.73 | KCNH2 (0.35) | KCNH2WNT3AACVR1 | |
| SCHEMBL13175886 | 0.72 | ACVR1 (0.36) | KCNH2ACVR1 | |
| SCHEMBL2927268 | 0.71 | TGFBR1 (0.41) | ACVR1EGFR | |
| SCHEMBL129502 | 0.71 | KDM1A (0.43) | CYP11B1 | |
| SCHEMBL30038718 | 0.71 | KDM1A (0.43) | CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885WNT3A 4383/4885ACVR1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.